Getting a cancer diagnosis remains to be a life-changing and emotionally devastating experience. We are unified in the mission to improve the treatment landscape for cancer patients by pursuing validated targets with novel approaches tailored to the patient's need.
Pipeline
Target/ Modality
Route
Cancer Indication
Lead Optimization
IND Enabling
Phase 1
TTX-810
TTX-564
TTX-114
MCL1 Inhibitor
CD3/CD33 Bispecific
HCK/BTK Inhibitor
i.v.
s.c.
oral
Solid Cancer
Hematological Cancer
Myelodysplastic Syndrome
Solid Cancer
Hematological Cancer
MCL1 inhibitor
TTX-810
MCL-1 acts as a "brake" on the apoptosis pathway which normally clears unwanted cells like cancer. Inhibition of MCL-1 rapidly induces cancer cell death.